Open-market purchases of Boundless Bio, Inc. (BOLD) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.
| Scan | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| Oct 21, 2026 | Kevin Tang / Tang Capital Management LLC10% Owner | $350K | Added | |||
| Four tranches Oct 16–20 at ~$2.33–$2.37 avg. Weighted avg ~$2.339. Current price $2.43 (+3.9%). Tang Capital is a serial biotech deep-value activist. Boundless Bio is a small-cap oncology company. | ||||||
| Jul 7, 2026 | Kevin Tang / Tang Capital Management10% Owner | $715K | Added | |||
| First tranche: June 25–29 at ~$2.50 avg. Filed June 29. Second tranche (July 2 filing): 107,463 additional shares at ~$2.50 ($268,880), filed July 6. Combined BOLD purchases ~$983K. Stock at $2.50 (flat). Form 425 on file suggests a potential merger or strategic combination. | ||||||
| Jul 7, 2026 | Kevin Tang / Tang Capital Management10% Owner | $269K | Added | |||
| Second Tang Capital tranche: June 30–July 2 at ~$2.50 avg. Filed July 6 (holiday-adjusted deadline for July 2 transactions). Stock at $2.50 (flat vs buy). See first BOLD entry for merger context. | ||||||
| Jul 6, 2026 | Kevin Tang10% Owner | $269K | Added | |||
| Purchased Jun 30–Jul 2 at $2.49–$2.54 avg via Tang Capital Management LLC. Tang stake now ~11.3% (2.64M shares). Now $2.50 (0.0%). Extrachromosomal DNA (ecDNA) oncology platform. | ||||||
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.